Anlotinib As a Molecular Targeted Therapy for Tumors

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 Jul 30

PMID 32724339

Citations 64

Authors

Yi Gao

Pengfei Liu

Ruihua Shi

Affiliations

Soon will be listed here.

Abstract

Angiogenesis has an essential role in tumor growth and metastasis, and blocking this pathway has been a successfully utilized strategy in the clinical treatment of cancer. Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis and received its first approval as a third-line treatment for refractory advanced non-small-cell lung cancer in May 2018 and its second approval as a second-line treatment for advanced soft-tissue sarcoma in June 2019 in the People's Republic of China. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. In the present review, the preclinical and clinical trials of anlotinib were summarized with a focus on safety evaluation and adverse event management.

Citing Articles

Pulmonary artery intimal sarcoma mimicking pulmonary thromboembolism: A case report and literature review.

Huang Y, Wang Y, Kong B, Zheng F, Ding Y, Hayford B Oncol Lett. 2025; 29(4):169.

PMID: 39963321 PMC: 11831714. DOI: 10.3892/ol.2025.14915.

Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.

Wang G, Wang Y, Jin C, Sun X Pharmacol Rep. 2025; .

PMID: 39899257 DOI: 10.1007/s43440-025-00700-1.

NGF-TrkA Axis Enhances PDGF-C-Mediated Angiogenesis in Osteosarcoma via miR-29b-3p Suppression: A Potential Therapeutic Strategy Using Larotrectinib.

Hou S, Cheng C, Chen W, Chang E, Lin C Life (Basel). 2025; 15(1).

PMID: 39860039 PMC: 11766545. DOI: 10.3390/life15010099.

State of Knowledge About Thyroid Cancers in the Era of COVID-19-A Narrative Review.

Bronowicka-Szydelko A, Rabczynski M, Dumas I, Fiodorenko-Dumas Z, Wojtczak B, Kotyra L Biomedicines. 2025; 12(12.

PMID: 39767735 PMC: 11672969. DOI: 10.3390/biomedicines12122829.

RTN4IP1 Contributes to ESCC via Regulation of Amino Acid Transporters.

Wei H, Zhao D, Zhi Y, Wu Q, Ma J, Xu J Adv Sci (Weinh). 2025; 12(8):e2406220.

PMID: 39757767 PMC: 11848606. DOI: 10.1002/advs.202406220.

References

Ryan C, Merimsky O, Agulnik M, Blay J, Schuetze S, Van Tine B . PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016; 34(32):3898-3905. DOI: 10.1200/JCO.2016.67.6684. View

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M . Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs. 2017; 36(2):332-339. DOI: 10.1007/s10637-017-0507-3. View

Butti R, Das S, Gunasekaran V, Yadav A, Kumar D, Kundu G . Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018; 17(1):34. PMC: 5817867. DOI: 10.1186/s12943-018-0797-x. View

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S . Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011; 26(7):823-33. DOI: 10.1007/s00384-011-1149-0. View

Ohm J, Carbone D . VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001; 23(2-3):263-72. DOI: 10.1385/IR:23:2-3:263. View

Shao L, Wang W, Song Z, Zhang Y . The efficacy and safety of anlotinib treatment for advanced lung cancer. Onco Targets Ther. 2019; 12:6549-6554. PMC: 6699585. DOI: 10.2147/OTT.S205674. View

Dobbin S, Cameron A, Petrie M, Jones R, Touyz R, Lang N . Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018; 104(24):1995-2002. PMC: 6268130. DOI: 10.1136/heartjnl-2018-313726. View

Cheville A, Kollasch J, Vandenberg J, Shen T, Grothey A, Gamble G . A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2012; 45(5):811-21. PMC: 4524515. DOI: 10.1016/j.jpainsymman.2012.05.006. View

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z . Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018; 4(11):1569-1575. PMC: 6248083. DOI: 10.1001/jamaoncol.2018.3039. View

10.

Lu J, Shi Q, Zhang L, Wu J, Lou Y, Qian J . Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. Front Oncol. 2019; 9:886. PMC: 6749025. DOI: 10.3389/fonc.2019.00886. View

11.

Saito S, Morishima K, Ui T, Hoshino H, Matsubara D, Ishikawa S . The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma. BMC Cancer. 2015; 15:82. PMC: 4345039. DOI: 10.1186/s12885-015-1065-8. View

12.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

13.

Regad T . Targeting RTK Signaling Pathways in Cancer. Cancers (Basel). 2015; 7(3):1758-84. PMC: 4586793. DOI: 10.3390/cancers7030860. View

14.

Wells Jr S, Gosnell J, Gagel R, Moley J, Pfister D, Sosa J . Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010; 28(5):767-72. PMC: 2834392. DOI: 10.1200/JCO.2009.23.6604. View

15.

Zwick E, Bange J, Ullrich A . Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001; 8(3):161-73. DOI: 10.1677/erc.0.0080161. View

16.

Bayraktar R, Van Roosbroeck K . miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev. 2017; 37(1):33-44. DOI: 10.1007/s10555-017-9724-7. View

17.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

18.

Reck M, Rabe K . Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):849-861. DOI: 10.1056/NEJMra1703413. View

19.

Morrison B . Soft tissue sarcomas of the extremities. Proc (Bayl Univ Med Cent). 2005; 16(3):285-90. PMC: 1200782. DOI: 10.1080/08998280.2003.11927915. View

20.

Jang H, Woo S, Song K, Cho H, Chay D, Hong S . API5 induces cisplatin resistance through FGFR signaling in human cancer cells. Exp Mol Med. 2017; 49(9):e374. PMC: 5628271. DOI: 10.1038/emm.2017.130. View